Tachyon Presents Preclinical Data on the Company's Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

HOUSTON--(BUSINESS WIRE)--Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Company’s first-in-class KDM4 inhibitor, at the American Association for Cancer Research...

Related Keywords

United States , American , Frank Perabo , American Association For Cancer Research , Ernestn Morial Convention Center , Tachyon Therapeutics Inc , Tachyon Therapeutics , American Association , Cancer Research , Annual Meeting , Convention Center , New Orleans , First In Class Inhibitor , Lysine Demethylase , Diffuse Largeb Cell Lymphoma , Chromatin Modifiers ,